Institute of Respiratory Disease, Department of Basic Medical Science, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", piazza Giulio Cesare 11, 70125, Bari, Italy.
Pneumology Department, "Di Venere" Hospital Bari, Bari, Italy.
J Endocrinol Invest. 2021 Apr;44(4):765-771. doi: 10.1007/s40618-020-01370-x. Epub 2020 Aug 9.
Hypovitaminosis D is a highly spread condition correlated with increased risk of respiratory tract infections. Nowadays, the world is in the grip of the Coronavirus disease 19 (COVID 19) pandemic. In these patients, cytokine storm is associated with disease severity. In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis.
In this retrospective, observational study, we analysed demographic, clinical and laboratory data of 42 patients with acute respiratory failure due to COVID-19, treated in Respiratory Intermediate Care Unit (RICU) of the Policlinic of Bari from March, 11 to April 30, 2020.
Eighty one percent of patients had hypovitaminosis D. Based on vitamin D levels, the population was stratified into four groups: no hypovitaminosis D, insufficiency, moderate deficiency, and severe deficiency. No differences regarding demographic and clinical characteristics were found. A survival analysis highlighted that, after 10 days of hospitalization, severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk (p = 0.019).
High prevalence of hypovitaminosis D was found in COVID-19 patients with acute respiratory failure, treated in a RICU. Patients with severe vitamin D deficiency had a significantly higher mortality risk. Severe vitamin D deficiency may be a marker of poor prognosis in these patients, suggesting that adjunctive treatment might improve disease outcomes.
维生素 D 缺乏症是一种高度流行的疾病,与呼吸道感染风险增加有关。如今,世界正处于 2019 年冠状病毒病(COVID-19)大流行之中。在这些患者中,细胞因子风暴与疾病严重程度相关。考虑到维生素 D 在免疫系统中的作用,本研究旨在分析因 COVID-19 导致急性呼吸衰竭的患者的维生素 D 水平,并评估其与疾病严重程度和预后的任何相关性。
在这项回顾性观察性研究中,我们分析了 2020 年 3 月 11 日至 4 月 30 日在巴里综合医院呼吸中级护理病房(RICU)治疗的 42 名因 COVID-19 导致急性呼吸衰竭的患者的人口统计学、临床和实验室数据。
81%的患者存在维生素 D 缺乏症。根据维生素 D 水平,将人群分为四组:无维生素 D 缺乏症、不足、中度缺乏和严重缺乏。在人口统计学和临床特征方面没有差异。生存分析表明,在住院 10 天后,严重维生素 D 缺乏症患者的死亡率为 50%,而维生素 D≥10ng/mL 的患者的死亡率为 5%(p=0.019)。
在 RICU 治疗的 COVID-19 急性呼吸衰竭患者中发现维生素 D 缺乏症的患病率很高。严重维生素 D 缺乏症患者的死亡率显著更高。严重维生素 D 缺乏症可能是这些患者预后不良的标志,提示辅助治疗可能改善疾病结局。